Checking in With Seven Gene Editing Stocks

July 8. 2024. 7 mins read

The toughest animals in the world are tardigrades. They’re found everywhere and can prosper in temperatures ranging from −459 °F (−273 °C) to 303 °F (151 °C). The Atlantic tells us that tardigrades can even tolerate New York, and perhaps their hardy nature is because they absorb DNA like a sponge. Observing the advantages other creatures possess in their own DNA gives the tardigrade inspiration for its own evolution over time.

The ability to edit DNA allows for mankind to begin playing God. Turns out that’s remarkably tough, and synthetic biology companies like Ginkgo Bioworks (DNA) are finding that out the hard way. While methods used to edit genes today like CRISPR are seeing some success, perhaps the best technology hasn’t even been invented yet. That’s why it’s important we see some wins that help prove the concept, and that first big win is coming from CRISPR Therapeutics (CRSP) with their historic first approval of a CRISPR-based medicine – CASGEVY.

CRISPR Gets CASGEVY Approval

CASGEVY is the first approved therapy in the U.S. that uses CRISPR and it’s no quick fix for sickle cell disease (SCD), a group of inherited blood disorders affecting approximately 100,000 people in the United States. Stem cells are collected from patients and sent to a lab where the actual CRISPR editing is done, and the entire process takes months, even up to a year. That’s according to an article by STAT news that hint

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.